Buchholzer Samanta, Thakachy Subha Sethu, Tchérémissinoff Livia, Boselie Franciscus, Triponez Frédéric, Faure Frédéric, Lopez Jean-Michel, Borner Urs, Kleinjung Tobias, Seebach Jörg D, Dulguerov Pavel, Marchal Francis
Department of Maxillofacial Surgery and Oral Medicine and Pathology, Geneva University Hospitals, Geneva, Switzerland.
Department of Surgery/ENT, Universiti Putra Malaysia (UPM), Serdang, Malaysia.
Front Surg. 2021 Sep 1;8:641945. doi: 10.3389/fsurg.2021.641945. eCollection 2021.
The aim of this study is to develop a simple and efficient screening questionnaire to be able to routinely monitor potential radioiodine therapy-induced complications. A new radioiodine 6 (RAI-6) questionnaire containing six questions adressing salivary, ocular, and nasal symptoms as well as quality of life was developed. Validation of the RAI-6 questionnaire was assessed with a group of fifty-four patients diagnosed with differentiated thyroid carcinoma treated post-operatively with radioiodine therapy, and in a group of fifty healthy volunteers. The patient's group was subdivided into subgroups according to the radioiodine dose received: 23 patients received less or 30 mCi, 28 patients received 100 mCi, and three patients received between 200 and 300 mCi. We asked the patients to complete the RAI-6 questionnaire in a retrospective manner, regarding their situation before radioiodine therapy and regarding their actual symptoms after radioiodine therapy. The time needed to complete the RAI-6 was also assessed both in patients and in healthy volunteers. The mean post radioiodine treatment RAI-6 score were significantly higher than the mean pre radioiodine RAI-6 scores ( < 0.001) and the scores of healthy participants ( < 0.001). The mean total RAI-6 scores increased significantly with increasing radioiodine dose. A total mean RAI-6 score of each question was also analysed and revealed that ocular and nasal discomfort as well as quality of life were the items which affected the patients most after radioiodine treatment. The mean time to fill the RAI-6 questionnaire was 2 min for patients and 49 s for healthy volunteers. The RAI-6 represents a new questionnaire which is easy and quick to complete. This simple screening tool can be recommended for general clinical practise and further epidemiological research.
本研究的目的是开发一种简单有效的筛查问卷，以便能够常规监测放射性碘治疗可能引起的并发症。我们开发了一种新的放射性碘6（RAI-6）问卷，其中包含六个问题，涉及唾液、眼部和鼻部症状以及生活质量。我们对一组54例接受放射性碘治疗的分化型甲状腺癌术后患者和一组50名健康志愿者进行了RAI-6问卷的验证。根据接受的放射性碘剂量，将患者组分为亚组：23例患者接受的剂量小于或等于30 mCi，28例患者接受100 mCi，3例患者接受的剂量在200至300 mCi之间。我们要求患者以回顾性方式完成RAI-6问卷，内容涉及放射性碘治疗前的情况以及放射性碘治疗后的实际症状。同时也评估了患者和健康志愿者完成RAI-6问卷所需的时间。放射性碘治疗后的RAI-6平均得分显著高于放射性碘治疗前的平均得分（<0.001）以及健康参与者的得分（<0.001）。RAI-6的总平均得分随着放射性碘剂量的增加而显著升高。我们还分析了每个问题的RAI-6平均总得分，结果显示眼部和鼻部不适以及生活质量是放射性碘治疗后对患者影响最大的项目。患者填写RAI-6问卷的平均时间为2分钟，健康志愿者为49秒。RAI-6是一种新的问卷，易于填写且快速。这种简单的筛查工具可推荐用于一般临床实践和进一步的流行病学研究。
